FLINT, Mich. — Oct. 10, 2017 — The nation’s largest independent provider of specialty pharmacy services dispensing limited-distribution drug VERZENIO™ (abemaciclib).

Diplomat Pharmacy, Inc. (NYSE: DPLO), is now filling prescriptions for newly approved VERZENIO™ (abemaciclib), a twice-daily oral therapy for advanced breast cancer.

To learn more about Diplomat’s oncology program, visit diplomat.is/areas-of-excellence/oncology.

VERZENIO is indicated as a combination treatment with FASLODEX® (fulvestrant) in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

VERZENIO is also approved as a monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

“This therapy represents yet another step forward in the way the health care community approaches treating advanced stages of this disease. We are proud to support patients dealing with breast cancer by dispensing VERZENIO,” said Joel Saban, Diplomat president.

According to the American Cancer Society, breast cancer is the second most common cancer in American women, with more than 250,000 diagnoses expected in 2017.

VERZENIO is manufactured by Eli Lilly and Company. For full prescribing information, click here.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise. 

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

### 

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

Twitter